Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06277219 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
A Phase 1 study of Advanced Solid Tumor, sponsored by Latticon Antibody Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 4
- Study locations
NCT06277219: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Latticon Antibody Therapeutics.
NCT06277219 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Latticon Antibody Therapeutics. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06277219, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Latticon Antibody Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
Primary Outcome
TEAEs
Conditions Studied
Interventions
- DRUG LAT010
- DRUG LAT010 + ICI
Study Locations (4)
Florida
- D&H Cancer Research Center - Margate
Utah
- Huntsman Cancer Institute - Salt Lake City
Shandong
- Cancer Hospital of Shandong First Medical University - Jinan
Zhejiang
- The First Affiliated Hospital of Zhejiang University School of Medicine - Hangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT06277219 shows while recruiting
NCT06277219 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which LAT010 is the first listed.
NCT06277219 reports a single indexed study location in Florida, Utah, Shandong.
Frequently Asked Questions
What is clinical trial NCT06277219 about?
NCT06277219 is a clinical study titled "A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)". This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalatio...
What is the current status of trial NCT06277219?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2027-03.
What conditions does trial NCT06277219 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06277219?
The interventions under investigation include: LAT010 (DRUG), LAT010 + ICI (DRUG).
Who is sponsoring clinical trial NCT06277219?
This trial is sponsored by Latticon Antibody Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06277219 being conducted?
This trial has 4 study locations across Florida, Utah, Shandong, Zhejiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06277219's enrollment target sits among peer trials
150 86th of 189 higher than 100 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI